Tyra Biosciences Holds $383.5M Cash, Doses First Patient in SURF303
Tyra Biosciences held $383.5 million in cash and marketable securities at Q1 2026, extending its operational runway into H2 2028. The company dosed its first patient in the Phase 2 SURF303 LG-UTUC study and expects SURF302 Phase 2 data in August and BEACH301 results in Q4.
1. Q1 Financial Results
Tyra Biosciences ended the first quarter of 2026 with $383.5 million in cash, cash equivalents and marketable securities, providing operational runway into the second half of 2028.
2. Dabogratinib 3x3 Clinical Strategy
The company advanced its dabogratinib 3x3 strategy targeting three FGFR3-driven indications: the first patient was dosed in the Phase 2a/b SURF303 study for low-grade upper tract urothelial carcinoma. More than 20 patients have enrolled in the Phase 2 SURF302 trial for intermediate-risk non-muscle invasive bladder cancer, and the BEACH301 achondroplasia program has cleared four safety sentinel dose levels.
3. Upcoming Clinical Readouts
Initial Phase 2 SURF302 three-month complete response data are expected in August 2026, initial safety and six-month height velocity results from the BEACH301 sentinel cohort are slated for the fourth quarter of 2026, and preliminary SURF303 outcomes are anticipated in 2027.
4. Corporate Governance Update
Tyra Biosciences appointed Habib Dable to its board of directors in April 2026, leveraging his three decades of biopharmaceutical leadership and track record of building blockbuster franchises.